SCHEMBL32669481

SCHEMBL32669481

CCC(C)(C)CC(=O)N[C@@H](CS)C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.52
MAPT P10636 1/20 0.52
THRB P10828 1/20 0.52
ALOX15 P16050 1/20 0.52
NFKB1 P19838 1/20 0.52
PTGS2 P35354 1/20 0.52
THPO P40225 1/20 0.52
RECQL P46063 1/20 0.52
BLM P54132 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
ACE P12821 3/20 0.47
FOLH1 Q04609 1/20 0.41
FNTA P49354 2/20 0.38
FNTB P49356 2/20 0.38
CA1 P00915 3/20 0.35
CA2 P00918 3/20 0.35
CA12 O43570 1/20 0.35
CA9 Q16790 1/20 0.35
NOD1 Q9Y239 1/20 0.34
PTGS1 P23219 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31446958 0.86 POLB (0.36) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL27397782 0.82 KDM4E (0.55) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL929419 0.82 KDM4E (0.55) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL20734733 0.82 KDM4E (0.55) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL31234077 0.81 KDM4E (0.53) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL32669483 0.78 KDM4E (0.50) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL22657901 0.77 KDM4E (0.63) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL1804545 0.77 KDM4E (0.63) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL1804546 0.77 KDM4E (0.63) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL31234818 0.75 KDM4E (0.55) KDM4EMAPTTHRBALOX15NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260035345-A1 N-PIVALOYLCYSTEINE DERIVATIVES FOR THE TREATMENT OF PRESBYOPIA LENTO BIO, INC. (US) 2026-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260035345-A1 N-PIVALOYLCYSTEINE DERIVATIVES FOR THE TREATMENT OF PRESBYOPIA CRYAB, CRYAA, CRYZ KDM4E 1882/4885MAPT 2090/4885THRB 3540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.